Today: 20 May 2026
Browse Category

NASDAQ:APLS 30 October 2025 - 17 May 2026

Apellis Exits Nasdaq; $41 Takeover Wraps, One Bet Left

Apellis Exits Nasdaq; $41 Takeover Wraps, One Bet Left

Biogen completed its acquisition of Apellis Pharmaceuticals last week, delisting Apellis from Nasdaq after accepting 82.4% of shares in a $41-per-share cash deal plus a contingent value right. Apellis became a Biogen subsidiary on May 14. The CVR will pay holders up to $4 if Syfovre sales meet specified targets. Biogen shares closed at $192.95 on Friday.
17 May 2026
··
Biogen Closes Apellis Deal; APLS Leaves Nasdaq As $5.6 Billion Rare-Disease Bet Begins

Biogen Closes Apellis Deal; APLS Leaves Nasdaq As $5.6 Billion Rare-Disease Bet Begins

Biogen has closed its acquisition of Apellis Pharmaceuticals, making Apellis a wholly owned subsidiary and delisting its shares from Nasdaq. Apellis shareholders receive $41 per share in cash plus a contingent value right tied to Syfovre sales. Biogen gains the drugs Empaveli and Syfovre, and expands into kidney disease. Biogen borrowed $2 billion to help finance the deal.
15 May 2026
···
Apellis Pharmaceuticals Vanishes From Nasdaq as Biogen’s Rare-Disease Bet Takes Over

Apellis Pharmaceuticals Vanishes From Nasdaq as Biogen’s Rare-Disease Bet Takes Over

Biogen closed its $5.3 billion acquisition of Apellis Pharmaceuticals, making Apellis a wholly owned subsidiary and ending its Nasdaq listing. Apellis shareholders receive $41 per share in cash plus a contingent value right tied to Syfovre sales. Biogen gains Syfovre and Empaveli, which generated $689 million in 2025 revenue. Biogen funded the deal with $2 billion in unsecured term loans.
14 May 2026
···
Apellis Pharmaceuticals Stock Nears Biogen’s $5.6 Billion Bid for Syfovre and Empaveli

Apellis Pharmaceuticals Stock Nears Biogen’s $5.6 Billion Bid for Syfovre and Empaveli

Biogen agreed to buy Apellis Pharmaceuticals for $5.6 billion, offering $41 per share in cash plus sales-based rights tied to the eye drug Syfovre. Apellis shares traded at $40.23 after the announcement. The deal includes a contingent value right worth up to $4 if Syfovre hits certain sales milestones. Apellis’ board and key shareholders, holding 14%, backed the offer, which is expected to close in the second quarter.
1 April 2026
···
Apellis’ $458M Shocker: FDA Win, Analyst Buzz & 20% Stock Whiplash

Apellis’ $458M Shocker: FDA Win, Analyst Buzz & 20% Stock Whiplash

Apellis Pharmaceuticals reported Q3 2025 revenue of $458.6 million and a $215.7 million net profit, but its stock fell about 21% after management warned of future losses. Syfovre sales in the U.S. were flat at $150.9 million, with modest injection growth and ongoing debate over its benefits. Empaveli gained FDA approval for rare kidney diseases in July. Analyst ratings and price targets remain divided.
30 October 2025
·

Stock Market Today

  • Goldman Sachs Sees North Asian Stocks Outperforming Southern Markets on AI and Energy Resilience
    May 19, 2026, 9:30 PM EDT. According to Goldman Sachs strategist Tim Moe, North Asian equity markets outperform South Asian ones due to greater resilience to energy shocks and strong AI sector growth. South Korea and Taiwan lead with tech-heavy indices, posting significant year-to-date gains, including over 80% in South Korea. In contrast, South Asia, including Indonesia, suffers a 25% decline due to lacking technology exposure and higher energy vulnerability. China's A-shares have gained 10% amid emerging deflation recovery and policy support, while H-shares lag given weaker tech earnings. Moe warns of potential market corrections as energy supply shocks loom, despite optimism for stable Japanese markets fueled by political stability and AI robotics growth.

Latest articles

Wall Street Hit by Yield Jolt With Nvidia Up Next

Wall Street Hit by Yield Jolt With Nvidia Up Next

20 May 2026
U.S. stock ETFs remained lower late Tuesday after Wall Street’s main indexes fell for a third straight session, pressured by rising Treasury yields and caution ahead of Nvidia’s earnings. The SPDR S&P 500 ETF dropped 0.7% to $733.73. The 10-year Treasury yield hit 4.687%, its highest since January 2025, before easing. Nvidia shares slipped 0.7% after hours, with traders bracing for a major move post-earnings.
Viavi Stock Drops After $500 Million Share Sale Plan — The Debt Move Investors Can’t Ignore

Viavi Stock Drops After $500 Million Share Sale Plan — The Debt Move Investors Can’t Ignore

20 May 2026
Viavi Solutions shares dropped 7.1% in after-hours trading Tuesday after the company announced a $500 million public stock offering aimed at repaying debt. The offering, unveiled just after the Nasdaq close, could add roughly 10.1 million new shares. Viavi plans to use proceeds to pay down a $450 million loan. Total debt would fall to $650 million, according to a preliminary SEC filing.
Analog Devices Shares Rally After $1.5B AI Power Deal Ahead of Earnings

Analog Devices Shares Rally After $1.5B AI Power Deal Ahead of Earnings

20 May 2026
Analog Devices agreed to acquire Empower Semiconductor for $1.5 billion in cash, sending ADI shares up 1.36% to $419.95 in after-hours trading after closing down 1.02%. The deal, approved by both boards, is expected to close in the second half of 2026 pending regulatory review. Empower CEO Tim Phillips will continue to lead integrated voltage regulator work after the merger.
Go toTop